JP5519702B2 - 鎮痛を目的とする、ｔ型カルシウムチャンネルの新規拮抗薬である毒素の同定 - Google Patents

鎮痛を目的とする、ｔ型カルシウムチャンネルの新規拮抗薬である毒素の同定 Download PDF

Info

Publication number
JP5519702B2
JP5519702B2 JP2011545778A JP2011545778A JP5519702B2 JP 5519702 B2 JP5519702 B2 JP 5519702B2 JP 2011545778 A JP2011545778 A JP 2011545778A JP 2011545778 A JP2011545778 A JP 2011545778A JP 5519702 B2 JP5519702 B2 JP 5519702B2
Authority
JP
Japan
Prior art keywords
peptide
channel
toxin
pain
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011545778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012514992A (ja
JP2012514992A5 (enExample
Inventor
ブリネ エマニュエル
エスクーバ ピエール
マルジェ ファブリス
ナルジェオ ジョエル
ラツンスキー ミシェル
Original Assignee
サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス）
ユニベルシテ ドゥ ニース ソフィア アンティポリ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス）, ユニベルシテ ドゥ ニース ソフィア アンティポリ filed Critical サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス）
Publication of JP2012514992A publication Critical patent/JP2012514992A/ja
Publication of JP2012514992A5 publication Critical patent/JP2012514992A5/ja
Application granted granted Critical
Publication of JP5519702B2 publication Critical patent/JP5519702B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
JP2011545778A 2009-01-15 2010-01-15 鎮痛を目的とする、ｔ型カルシウムチャンネルの新規拮抗薬である毒素の同定 Active JP5519702B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR09/00174 2009-01-15
FR0900174A FR2940973B1 (fr) 2009-01-15 2009-01-15 Identification de nouvelles toxines antagonistes de canaux calcique type-t a visee analgesique
PCT/FR2010/000037 WO2010081971A1 (fr) 2009-01-15 2010-01-15 Identification de nouvelles toxines antagonistes de canaux calciques type-t a visee analgesique

Publications (3)

Publication Number Publication Date
JP2012514992A JP2012514992A (ja) 2012-07-05
JP2012514992A5 JP2012514992A5 (enExample) 2013-02-07
JP5519702B2 true JP5519702B2 (ja) 2014-06-11

Family

ID=40834515

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545778A Active JP5519702B2 (ja) 2009-01-15 2010-01-15 鎮痛を目的とする、ｔ型カルシウムチャンネルの新規拮抗薬である毒素の同定

Country Status (7)

Country Link
US (1) US8664179B2 (enExample)
EP (1) EP2387581B1 (enExample)
JP (1) JP5519702B2 (enExample)
CA (1) CA2749824C (enExample)
ES (1) ES2524564T3 (enExample)
FR (1) FR2940973B1 (enExample)
WO (1) WO2010081971A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014045126A2 (en) * 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
US20220089663A1 (en) * 2019-01-18 2022-03-24 Memorial Sloan Kettering Cancer Center PROTEINS AND FLUOROPHORE-CONTAINING COMPOUNDS SELECTIVE FOR NaV1.7
US20230241259A1 (en) * 2020-06-10 2023-08-03 Memorial Sloan Kettering Cancer Center IMAGING COMPOUNDS SELECTIVE FOR NaV1.7

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776896A (en) * 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
US5756663A (en) * 1996-01-03 1998-05-26 Zeneca Limited Antiarrhythmic peptide from venom of spider Grammostola spatulata
AU6109698A (en) 1998-02-20 1999-09-06 Zeneca Limited Analgesic peptides from venom of (grammostola spatulata) and use thereof

Also Published As

Publication number Publication date
WO2010081971A1 (fr) 2010-07-22
JP2012514992A (ja) 2012-07-05
EP2387581A1 (fr) 2011-11-23
EP2387581B1 (fr) 2014-10-08
CA2749824A1 (fr) 2010-07-22
FR2940973A1 (fr) 2010-07-16
FR2940973B1 (fr) 2013-05-24
US8664179B2 (en) 2014-03-04
ES2524564T3 (es) 2014-12-10
US20120040909A1 (en) 2012-02-16
CA2749824C (fr) 2017-05-02

Similar Documents

Publication Publication Date Title
Loughnan et al. Chemical and functional identification and characterization of novel sulfated α-conotoxins from the cone snail conus a nemone
Shon et al. A noncompetitive peptide inhibitor of the nicotinic acetylcholine receptor from Conus purpurascens venom
Salinas et al. The receptor site of the spider toxin PcTx1 on the proton‐gated cation channel ASIC1a
Pinto et al. CiC3-1a-mediated chemotaxis in the deuterostome invertebrate Ciona intestinalis (Urochordata)
JP2019530468A (ja) 修飾されたリガンド依存性イオンチャネルおよび使用の方法
JP2012501973A (ja) 痛みの治療に関する薬剤及び方法
US8030442B2 (en) Treatment of injury to the brain by inhibition of acid sensing ion channels
CN101745097A (zh) 特异阻断乙酰胆碱受体的海南产α-芋螺毒素及其用途
CN102977201B (zh) 少棘蜈蚣多肽毒素mu-SLPTX-Ssm6a及其基因和应用
JP2006051033A (ja) 電位依存性カルシウムチャンネルアンタゴニストおよび方法
JP5487117B2 (ja) ニューロテンシン受容体３に由来するペプチドおよび精神疾患の治療におけるその使用
JP2012514992A (ja) 鎮痛を目的とする、ｔ型カルシウムチャンネルの新規拮抗薬である毒素の同定
JP4447783B2 (ja) 新規なぺプチド類
CN102050874B (zh) 虎纹捕鸟蛛毒素-xvi的制备方法
JP2003520022A (ja) ヒトのバニロイドレセプターｖｒ１をコードするｄｎａ
EP2294082A1 (en) Compositions and methods for modulating nicotinic/nmda receptor function
Rose et al. C-type natriuretic peptide inhibits L-type Ca2+ current in rat magnocellular neurosecretory cells by activating the NPR-C receptor
CA3045790C (en) Peptide modulator of purinergic receptors
Ohman et al. Use of surface plasmon resonance coupled with mass spectrometry reveals an interaction between the voltage-gated sodium channel type X α-subunit and caveolin-1
RU2404245C1 (ru) Полипептид актинии, обладающий анальгетическим действием
JP4512273B2 (ja) 新規なぺプチド類
CA2066491C (en) Human neurokinin-1 receptor
US20220002359A1 (en) Voltage-Gated Calcium Channel Auxilliary Subunit Alpha 2 Delta and Uses Thereof
RU2521657C1 (ru) Анальгетический пептид из морской анемоны urticina grebelnyi
Farley et al. SARS-CoV-2 S1 spike protein peptides inhibit alpha 7 nAChRs and are counteracted by a PAM at alpha 7

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140403

R150 Certificate of patent or registration of utility model

Ref document number: 5519702

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250